June 23 at 9:00 am PDT / 12:00 pm EDT  

This session will begin with a conversation with American Cancer Society CEO, Karen Knudsen followed by a panel discussion.

Researchers have made significant progress in treating cancers, with a range of new interventions providing important options for patients. However, for myriad reasons, much of the innovation to date is indicated to treat patients with advanced disease. Today, screening tests are widely available for only five cancer types. For many patients, cancer is diagnosed when they present with symptoms, with the result that treatment is initiated only after the disease has already progressed. A new wave of multi-cancer early detection (MCED) tests has the potential to identify cancers earlier, opening doors to research and treatment opportunities for cancers at earlier stages than before. Learn more about how earlier detection has the potential to shift the research paradigm and drive new advances in cancer treatment.
 

Part 1

Guest

Karen Knudsen 
CEO, American Cancer Society
 

Moderator

Michael Milken 
Chairman, Milken Institute
 

Part 2

Moderator

Jody Hoyos 
President and Chief Operating Officer, Prevent Cancer Foundation
 

Speakers

Jeff Allen 
President and CEO, Friends of Cancer Research

Camille Hertzka 
Vice President, Head of Medical Affairs, US Oncology, AstraZeneca

Josh Ofman 
Chief Medical Officer and External Affairs, GRAIL

Azra Raza 
Professor of Medicine and Director, Myelodysplastic Syndrome Center, Columbia University
 

Materials

Seizing the Transformative Opportunity of Multi-cancer Early Detection

Late-Stage Diagnosis of Unscreened Cancer: a Health Disparity

The First Cell Azra Raza